1. Outcomes of Alprostadil As an Adjuvant Therapy with Indirect Angiosomal Revascularization in Patients with Critical Limb Ischemia after Failure of Direct Revascularization.
- Author
-
Alhewy MA, Abdo EM, Ghazala EAE, Khamis AA, Gado H, Abd-Elgawad WAA, Abdelhafez AA, El Sayed A, Khedr AM, and Mosaed HAM
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Time Factors, Treatment Failure, Endovascular Procedures adverse effects, Infusions, Intravenous, Vasodilator Agents administration & dosage, Vasodilator Agents adverse effects, Lower Extremity blood supply, Amputation, Surgical, Treatment Outcome, Risk Factors, Retrospective Studies, Alprostadil administration & dosage, Alprostadil adverse effects, Peripheral Arterial Disease physiopathology, Peripheral Arterial Disease therapy, Peripheral Arterial Disease diagnostic imaging, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease drug therapy, Ischemia physiopathology, Ischemia therapy, Ischemia drug therapy, Ischemia diagnosis, Critical Illness, Ankle Brachial Index, Vascular Patency, Limb Salvage
- Abstract
Background: This study was carried out to assess the effectiveness of alprostadil (prostaglandin E1) when used as an adjuvant therapy with indirect revascularization in patients with critical limb ischemia (CLI) after the failure of direct revascularization (DR)., Methods: At our centers, 120 patients suffering from infrainguinal peripheral arterial disease with CLI underwent a failed trial of DR procedure, all revascularization procedures were endovascular. Median follow-up was 2 years and 2.5 years for patients with and without diabetes mellitus (DM). In the alprostadil group, the mean age was 63.41 ± 12.52; 36 (60%) for males and 24 (40%) for females. Post-endovascular intervention alprostadil was administrated immediately postoperatively by intravenous infusion of 40 μg alprostadil diluted in 100 ml of normal saline, over 2 hr every 12 hr for 6 days., Results: In the alprostadil group, the mean ± standard deviation (SD) of the baseline ankle-brachial index (ABI) was 0.45 ± 0.175, while the mean ± SD of ABI at the end of our study was 0.65 ± 0.216 with a difference from the baseline of 0.2 ± 0.041 (P value = 0.08, <0.05 meaning that it is significant). Our 1-month primary patency rate was 93.3%, while our 3- and 6-month patency rate was 92.9%. In the control group, the mean ± SD of the baseline ABI was 0.68 ± 0.22, while the mean ± SD of ABI at the end of our study was 0.69 ± 0.23 with a difference from the baseline of 0.01 ± 0.01 (P value >0.05 meaning that it is nonsignificant) 1-month patency rate was 89%, while 3- and 6-month patency rate was 75%. When we compared the patient's leg vessels before and after our intervention, we found that the percentage of the no-runoff-vessels group decreased from 10 (16.7%) to 4 (6.67%). One-runoff-vessel group percentage dropped from 40 (66.7%) to 36 (60%), whereas, in the two-runoff-vessel group, the percentage increased from 10 (16.7%) to 20 (33.3%). We evaluate leg arteries; we do no pedal arch intervention in the alpostradil group. Out of the total of 60 patients, limb salvage occurred in 58 (96.7%) patients, and 2 (3.3%) patients underwent below-the-knee amputation before the study ended., Conclusions: Our results show the efficacy and safety of alprostadil as an adjuvant therapy with indirect angiosomal revascularization in patients with tissue loss due to CLI., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF